Distinguished in Neuroendocrine Carcinoma of the Cervix

David Azria

CRLC Val D'Aurelle
Montpellier, FR 
Distinguished in Neuroendocrine Carcinoma of the Cervix
CRLC Val D'Aurelle
Montpellier, FR 
OverviewLocationsClinical Research

Overview

David Azria practices in Montpellier, France. Mr. Azria is rated as a Distinguished expert by MediFind in the treatment of Neuroendocrine Carcinoma of the Cervix. His top areas of expertise are Prostate Cancer, Breast Cancer, Neuroendocrine Carcinoma of the Cervix, Mastectomy, and Prostatectomy.

His clinical research consists of co-authoring 382 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

CRLC Val d'Aurelle
Montpellier, 34000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Other
Study Drugs: Cisplatin, Gemcitabine
Study Phase: Not Applicable
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Apalutamide, Luteinising Hormone Releasing Hormone agonist
Study Phase: Phase 3
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.
Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.
Enrollment Status: Completed
Publish Date: November 30, 2022
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
Enrollment Status: Completed
Publish Date: June 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

382 Total Publications

Guidelines for external radiotherapy and brachytherapy procedures: 4th edition.
Guidelines for external radiotherapy and brachytherapy procedures: 4th edition.
Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Azria's expertise for a condition
ConditionClose
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile